Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.
about
Statin withdrawal in people with dementiaIndustry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statinsAntiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysisCurrent and Emerging Uses of Statins in Clinical Therapeutics: A ReviewDo statins impair cognition? A systematic review and meta-analysis of randomized controlled trialsSphingolipids and phospholipids in insulin resistance and related metabolic disorders.Effects of LEP G2548A and LEPR Q223R Polymorphisms on Serum Lipids and Response to Simvastatin Treatment in Chinese Patients With Primary Hyperlipidemia.Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study.A prospective stratified case-cohort study on statins and multiple adverse events in Japan.Pharmacometabolomics of statin responsePredictors of type 2 diabetes in a nationally representative sample of adults with psychosis.Characterization of diabetes risk factors in patients prescribed chronic statin therapy.Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--EffectiveSafety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants.Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population.SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.Treatment Options for Statin-Associated Muscle Symptoms.Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.SLCO1B1 Polymorphisms and Statin-Induced Myopathy.Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database.Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review.Pravastatin activates activator protein 2 alpha to augment the angiotensin II-induced abdominal aortic aneurysms.Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.The strategies to control prostate cancer by chemoprevention approaches.Treatment of cholesterol in the elderly: statins and beyond.How low an LDL-C should we go with statin therapy?An update on the benefits and risks of rosuvastatin therapy.Addressing statin adverse effects in the clinic: the 5 Ms.Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials.Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.A review of statin use and prostate cancer.Sphingosine-1-phosphate receptor subtype 2 signaling in endothelial senescence-associated functional impairments and inflammation.Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.Drug-Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism.Statin therapy across the lifespan: evidence in major age groups.
P2860
Q24186720-33DF2ADA-34F8-4E8A-BD89-4B0ED988CF5DQ24289041-1828FBC0-621C-4B85-BDBF-AB8B7258F711Q28076042-96620069-206C-4ED2-94D5-BD2CD4273090Q28076346-4D1B13EB-4A21-41CD-83C1-E9FD74C03305Q28085282-9DF8AABA-1ECD-4911-9A7E-9C1396FC5DB9Q30241943-49962AFF-8679-402F-ADEF-FB4B26FE69DEQ30277140-A9CACE66-26B1-469E-BBBF-2B08E4C8836AQ31131725-E9F60EAB-0A52-4EC5-A807-51669008409DQ33584216-65E3461C-3117-4CB1-A07E-73BC947460ECQ33746373-C20428AF-3B5C-4C68-A378-EC8F4012A4BBQ33915509-AB6F37DC-CA39-4F82-AAB1-B4DF395B1D11Q34039706-02EC98C4-4F53-4E6F-86A5-FCFF474DB037Q34411415-DDA0A476-8765-4A24-94BB-11C99A1987B4Q34549418-CEE3DC67-F425-49D3-9EF7-2F7FD105ADB5Q34680467-957D444C-1FE8-4B6A-AEB6-F891DC375899Q35021842-C39B8748-82C1-4B4C-9115-C2E86BE70BF4Q35793619-A35B85AF-2358-4901-AE48-4058F17157C8Q35918786-AC9EF8F4-0070-4022-B66D-9456E513ADC3Q36102162-C76A5B53-CFAD-436D-A3F1-CC23AEC8E941Q36184009-65546168-4ACA-45AD-8DD3-B85B379B3486Q36294394-937C4DF3-69A8-4F61-A75E-9E6B1028DA02Q36307308-9AE0510E-3ACD-4A2E-8238-DCF00B9203BEQ37410969-59AFBE20-FEB1-44DC-8895-23881C1D0BB0Q37433115-616933E0-21EE-4E90-8692-68D0FBF602D2Q37612171-ECD7EA10-E443-48DB-8D0F-07A403CC9CD1Q37714650-510A16A7-5EE4-4A3C-9C88-85702F8479F8Q37716363-7A68C2C4-484B-41F0-AF00-15F57EE13697Q38161516-40EFD7F1-19E2-4667-A722-86F6532FA066Q38175776-15E67607-6C4B-46A0-92E9-129B9DCD1B41Q38176272-86409E72-C83F-4A15-AEC3-C1E5392EEC37Q38176273-1459E653-2D7F-4665-AA7A-91C5AC55E7A3Q38200826-293187CF-5C53-48C0-BEB8-1770D0683811Q38207488-6147DCC5-9DEF-43D2-B6EB-92D506E5166FQ38229263-F5456804-5E22-47E5-9F2E-63947664996CQ38244605-46072D30-5E01-4C41-9F92-816F30276116Q38272644-43B80BE4-BE45-497D-B045-C364F0A395DAQ38374482-7BE6562E-EE27-4F35-81A0-6C3BF6C20EACQ38563329-03262C34-7AD2-48AF-8D6B-B9877A2428F6Q38600327-2D38AB39-53C2-42AB-93C3-0F2F6F84648BQ38660929-C1786BD0-F109-4C3D-8EA3-7674CAAD2EDA
P2860
Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Comparative tolerability and h ...... randomized, controlled trials.
@ast
Comparative tolerability and h ...... randomized, controlled trials.
@en
Comparative tolerability and h ...... randomized, controlled trials.
@nl
type
label
Comparative tolerability and h ...... randomized, controlled trials.
@ast
Comparative tolerability and h ...... randomized, controlled trials.
@en
Comparative tolerability and h ...... randomized, controlled trials.
@nl
prefLabel
Comparative tolerability and h ...... randomized, controlled trials.
@ast
Comparative tolerability and h ...... randomized, controlled trials.
@en
Comparative tolerability and h ...... randomized, controlled trials.
@nl
P2093
P1476
Comparative tolerability and h ...... randomized, controlled trials.
@en
P2093
Huseyin Naci
Jasper Brugts
P304
P356
10.1161/CIRCOUTCOMES.111.000071
P577
2013-07-09T00:00:00Z